Literature DB >> 19555901

Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development.

Helena Lo1, Christoph M Tang, Rachel M Exley.   

Abstract

Neisseria meningitidis remains an important cause of severe sepsis and meningitis worldwide. The bacterium is only found in human hosts, and so must continually coexist with the immune system. Consequently, N meningitidis uses multiple mechanisms to avoid being killed by antimicrobial proteins, phagocytes, and, crucially, the complement system. Much remains to be learnt about the strategies N meningitidis employs to evade aspects of immune killing, including mimicry of host molecules by bacterial structures such as capsule and lipopolysaccharide, which poses substantial problems for vaccine design. To date, available vaccines only protect individuals against subsets of meningococcal strains. However, two promising vaccines are currently being assessed in clinical trials and appear to offer good prospects for an effective means of protecting individuals against endemic serogroup B disease, which has proven to be a major challenge in vaccine research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555901     DOI: 10.1016/S1473-3099(09)70132-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  46 in total

1.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

2.  Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Authors:  Kathleen Y Dunphy; Peter T Beernink; Barbara Brogioni; Dan M Granoff
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

3.  Phosphoryl moieties of lipid A from Neisseria meningitidis and N. gonorrhoeae lipooligosaccharides play an important role in activation of both MyD88- and TRIF-dependent TLR4-MD-2 signaling pathways.

Authors:  Mingfeng Liu; Constance M John; Gary A Jarvis
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

4.  Genome sequence of Neisseria meningitidis serogroup B strain H44/76.

Authors:  J R Piet; R A G Huis in 't Veld; B D C van Schaik; A H C van Kampen; F Baas; D van de Beek; Y Pannekoek; A van der Ende
Journal:  J Bacteriol       Date:  2011-03-04       Impact factor: 3.490

5.  Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.

Authors:  Giannina Izquierdo; Juan Pablo Torres; M Elena Santolaya; M Teresa Valenzuela; Jeannette Vega; May Chomali
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Draft genome sequences of two Neisseria meningitidis serogroup C clinical isolates.

Authors:  Enrico Lavezzo; Stefano Toppo; Luisa Barzon; Claudio Cobelli; Barbara Di Camillo; Francesca Finotello; Elisa Franchin; Denis Peruzzo; Gianna Maria Toffolo; Marta Trevisan; Giorgio Palù
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

7.  Host defense pathways: role of redundancy and compensation in infectious disease phenotypes.

Authors:  Simone Nish; Ruslan Medzhitov
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

8.  Meningococcal Vaccine: Which, When and for Whom?

Authors:  S P Gorthi; A K Nagpal
Journal:  Med J Armed Forces India       Date:  2011-07-21

9.  Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum.

Authors:  Elena Del Tordello; Irene Vacca; Sanjay Ram; Rino Rappuoli; Davide Serruto
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

10.  Investigating the role of mitochondrial haplogroups in genetic predisposition to meningococcal disease.

Authors:  Antonio Salas; Laura Fachal; Sonia Marcos-Alonso; Ana Vega; Federico Martinón-Torres
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.